Share on LinkedInShare on LinkedIn

ARTICLE · 02 FEBRUARY 2016

Pfizer v. Lee: A Patent Term Adjustment Double Standard?

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Explore more from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

In Pfizer v. Lee (No. 2015-1265, January 22, 2016), the Federal Circuit upheld the USPTO's determination that the toll period for A-type patent term adjustment delay stops upon the mailing of a deficient USPTO paper.

United StatesIntellectual Property

In Pfizer v. Lee (No. 2015-1265, January 22, 2016), the Federal Circuit upheld the U.S. Patent and Trademark Office's (USPTO) determination that the toll period for A-type patent term adjustment (PTA) delay stops upon the mailing of a deficient USPTO paper. Conversely, by statute, an applicant's submission of a deficient paper to the USPTO does not stop the toll period for applicant delay that is subtracted from PTA accrued due to USPTO delay. Before further considering the Pfizer decision and its contrast with applicant delay, let's start with a reminder of PTA rules.

PTA Overview

35 U.S.C. § 154 provides for three types of USPTO delay in prosecution that entitle a patent to an extension of term beyond the standard term of the patent:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from